Exclusive: Therini raises $36M, will target fibrin protein for Alzheimer's and diabetic macular edema
Therini Bio has raised a $36 million Series A and will head to the clinic with an antibody that neutralizes fibrin, a blood clotting protein, that it hopes could have broad applications in tamping down inflammation.
The funding round, which included investments from Eli Lilly, Sanofi and Merck, will let Therini move toward tests in Alzheimer’s disease and diabetic macular edema, the company told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.